Wells Fargo & Company Boosts Glaukos (NYSE:GKOS) Price Target to $103.00

Glaukos (NYSE:GKOS – Free Report) had its price objective hoisted by Wells Fargo & Company from $83.00 to $103.00 in a research report report published on Thursday morning, Benzinga reports. They currently have an overweight rating on the medical instruments supplier’s stock. A number of other equities analysts have also recently weighed in on the […]

Related Keywords

Marc Stapley ,Piper Sandler ,Josephe Gilliam ,Lisanti Capital Growth ,Wells Fargo Company ,Glaukos Company Profile ,Morgan Stanley ,Glaukos Corporation ,Wealthcare Advisory Partners ,Needham Company ,Charles Schwab Investment Management Inc ,Free Report ,Wells Fargo ,Moderate Buy ,Stock Down ,Get Free Report ,Director Marc Stapley ,Schwab Investment Management ,Advisory Partners ,Capital Growth ,Iron Triangle Partners ,Glaukos Daily ,Glaukos ,Nyse Gkos ,Gkos ,Medical ,Boost Price Target ,Wells Fargo Amp Company ,